Patent · US Expired

Recombinant MVA virus, and the use thereof

US6440422B1 · kind B1 · utility

44Cited by

4References

33Claims

0Family size

Assignee

GSF-Forshungszentrum für Umwelt und Gesundheit, GmbH · DE

Inventors

Gerd Sutter · Munich, DE
Marion Ohlmann · Munich, DE
Volker Erfle · Munich, DE

Key dates

Filing date	Jan 2, 1998
Grant date	Aug 27, 2002
Priority date	—
Expiry date	Jan 2, 2018

Classification

Technology area (CPC Y)Emerging Cross-Sectional Technologies
CPC primaryY02A50/30
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

The present invention relates to recombinant vaccinia viruses derived from the modified vaccinia virus Ankara (MVA) and containing and capable of expressing foreign genes which are inserted at the site of a naturally occurring deletion in the MVA genome, and the use of such recombinant MVA viruses for the production of polypeptides, e.g. antigens or therapeutic agents, or viral vectors for gene therapy, and the use of such recombinant MVA viruses encoding antigens as vaccines.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.